{"id":9045,"date":"2021-02-05T00:00:00","date_gmt":"2021-02-05T00:00:00","guid":{"rendered":""},"modified":"2021-02-05T00:00:00","modified_gmt":"2021-02-05T00:00:00","slug":"five-year-efficacy-and-safety-of-tildrakizumab-in-patients-with-moderate-to-severe-psoriasis-who-respond-at-week-28-pooled-analyses-of-two-randomised-phase-3-clinical-trials-resurface-1-and-resurfac","status":"publish","type":"post","link":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/2021\/02\/05\/five-year-efficacy-and-safety-of-tildrakizumab-in-patients-with-moderate-to-severe-psoriasis-who-respond-at-week-28-pooled-analyses-of-two-randomised-phase-3-clinical-trials-resurface-1-and-resurfac\/","title":{"rendered":"Five-year efficacy and safety of tildrakizumab in patients with moderate to severe psoriasis who respond at week 28: pooled analyses of two randomised phase 3 clinical trials (reSURFACE 1 and reSURFACE 2)."},"content":{"rendered":"<p>The phase 3 reSURFACE 1 and reSURFACE 2 (NCT01722331\/NCT01729754) trials of the anti-interleukin-23p19 monoclonal antibody tildrakizumab for psoriasis treatment are complete.We present 5-year pooled data from reSURFACE 1 and reSURFACE [&#8230;]\n","protected":false},"excerpt":{"rendered":"<p>The phase 3 reSURFACE 1 and reSURFACE 2 (NCT01722331\/NCT01729754) trials of the anti-interleukin-23p19 monoclonal antibody tildrakizumab for psoriasis treatment are complete.We present 5-year pooled data from reSURFACE 1 and reSURFACE &#8230;<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[86],"tags":[],"acf":[],"_links":{"self":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts\/9045"}],"collection":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/comments?post=9045"}],"version-history":[{"count":0,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts\/9045\/revisions"}],"wp:attachment":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/media?parent=9045"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/categories?post=9045"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/tags?post=9045"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}